Department of Oral and Maxillofacial Surgery, University Medical Centre of the Johannes Gutenberg University, Mainz, Germany.
Oral Oncol. 2010 Jul;46(7):543-8. doi: 10.1016/j.oraloncology.2010.03.025.
Costimulatory molecules have complementary effects on T-cell activation and their balance may control the development of oral cancer. The aim of this study was to determine the relevance of cytotoxic T-lymphocyte antigen 4 (CTLA-4), CD28 and inducible costimulator (ICOS) polymorphisms in oral squamous cell carcinoma (OSCC). Genotyping for CTLA-4 (-1661 A/G and +49 A/G), CD28 (0 C/G and +3160 G/T) and ICOS (+637 A/C and +1599 C/T) was performed in the 83 patients with OSCC, compared to the 40 unrelated healthy volunteers as controls. The genotype CTLA-4 -1661 was significantly different between the patient group and the control group. The allele CTLA-4 -1661 G was significantly found more frequent in patients with OSCC (p=0.001). In bivariate analysis, noticeable differences between OSCC and controls were seen. The combinations CTLA-4 -1661 G/G and CTLA-4 +49 A/G, ICOS +1559 C/T and ICOS +1559 C/C each with CTLA-4 -1661 G/G, ICOS +637 C/C and ICOS +637 A/C each with CTLA-4 -1661, CTLA-4 -1661 A/G and ICOS +637 C/C, CD28 +3160 G/T and CTLA-4 -1661 A/A and CD28 +3160 G/T and CTLA-4 -1661 A/G were seen in the patient group only. Especially the polymorphisms of the CTLA-4 -1661-genotype - alone and in combination with other T cell regulator polymorphisms - seem to be possible predisposing factors for OSCC. Therefore, they might be future targets for a primary prophylaxis or an individualised therapy.
共刺激分子对 T 细胞的激活有互补作用,其平衡可能控制口腔癌的发展。本研究的目的是确定细胞毒性 T 淋巴细胞抗原 4(CTLA-4)、CD28 和诱导共刺激分子(ICOS)多态性在口腔鳞状细胞癌(OSCC)中的相关性。对 83 例 OSCC 患者和 40 名无关的健康志愿者进行 CTLA-4(-1661A/G 和 +49A/G)、CD28(0C/G 和 +3160G/T)和 ICOS(+637A/C 和 +1599C/T)的基因分型。CTLA-4-1661 基因型在患者组和对照组之间有显著差异。等位基因 CTLA-4-1661G 在 OSCC 患者中明显更常见(p=0.001)。在双变量分析中,OSCC 组和对照组之间有显著差异。组合 CTLA-4-1661G/G 和 CTLA-4+49A/G、ICOS+1559C/T 和 ICOS+1559C/C 各与 CTLA-4-1661G/G、ICOS+637C/C 和 ICOS+637A/C 各与 CTLA-4-1661、CTLA-4-1661A/G 和 ICOS+637C/C、CD28+3160G/T 和 CTLA-4-1661A/A 和 CD28+3160G/T 和 CTLA-4-1661A/G 仅在患者组中可见。特别是 CTLA-4-1661 基因型的多态性-单独存在或与其他 T 细胞调节因子的多态性结合-似乎是 OSCC 的可能易感因素。因此,它们可能是初级预防或个体化治疗的未来靶点。